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Abstract
AIM: To provide appropriate treatment, it is crucial 
to share the clinical status of pancreas head cancer 
among multidisciplinary treatment members. 
METHODS: A retrospective analysis of the medical 
records of 113 patients who underwent surgery for 
pancreas head cancer from January 2008 to December 
2012 was performed. We developed preoperative 
defining system of pancreatic head cancer by describing 
“resectability - tumor location - vascular relationship 
- adjacent organ involvement - preoperative CA19-9 
(initial bilirubin level) - vascular anomaly”. The 
oncologic correlations with this reporting system were 
evaluated. 
RESULTS: Among 113 patients, there were 75 patients 
(66.4%) with resectable, 34 patients (30.1%) with 
borderline resectable, and 4 patients (3.5%) with locally 
advanced pancreatic cancer. Mean disease-free survival 
was 24.8 mo (95%CI: 19.6-30.1) with a 5-year disease-
free survival rate of 13.5%. Pretreatment tumor size 
≥ 2.4 cm [Exp(B) = 3.608, 95%CI: 1.512-8.609, P  = 
0.044] and radiologic vascular invasion [Exp(B) = 5.553, 
95%CI: 2.269-14.589, P  = 0.002] were independent 
predictive factors for neoadjuvant treatment. Borderline 
resectability [Exp(B) = 0.222, P  = 0.008], pancreatic 
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Retrospective Study
Preoperative defining system for pancreatic head cancer 
considering surgical resection
patients’ chance of survival and prognosis based on 
clinically available information. However, there is no 
generalized preoperative defining system effectively 
showing the extent of pancreatic cancer and tumor 
biology. 
It would be very helpful if a well-designed pre-
operative defining system of pancreatic cancer could: 
(1) estimate the clinical stage of cancer (tumor 
extension); (2) give practical information for designing 
the extent of surgery and choosing the treatment 
modality; (3) play a role as an effective communication 
tool among multidisciplinary team members; and (4) 
help predict oncologic outcomes. 
In this study, we propose a preoperative defining 
system in patients with pancreatic head cancer 
considering curative resection. Our system may be 
useful in improving communication and developing 
strategies for treating pancreatic cancer.
MATERIALS AND METHODS
Principles of the new preoperative defining system
Based on radiological interpretation of preoperative 
images, resected pancreatic head cancers are intended 
to be described as the following structures: Pancreatic 
head cancer; “Resectability (tumor size, cm) - Tumor 
location-vascular relationship (length of involved 
segment (cm)/Circumferential involvement (%) - 
Adjacent organ involvement - Preoperative CA19-9 
(initial bilirubin level) - Vascular anomaly”. 
Radiological resectability follows the National 
Comprehensive Cancer Network (NCCN) guideline[5]. 
If there is no vascular involvement, no adjacent organ 
invasion, and no clinical metastasis, no descriptions 
were added to this defining system for explaining this 
negative information. Important abbreviations are 
listed in Table 1.
Organs such as the duodenum and bile duct that 
will be removed by standard pancreaticoduodenectomy 
were not described even in cases of cancer invasion. 
However, if the tumor invaded the pylorus or antrum, 
it was added as a factor of adjacent organ invasion. 
Figure 1 shows the examples for application of the 
new defining system in patients with pancreatic head 
cancer.
Patient data collection
From January 2008 to December 2012, medical 
records and preoperative image studies of patients 
with resected pancreatic cancer were retrospectively 
reviewed. The clinic-pathological variables were 
checked. In particular, preoperative clinical information 
such as resectability, radiologic tumor size, tumor 
location, preoperative serum CA19-9, preoperative 
serum bilirubin, and adjusted CA19-9 (initial serum 
level of CA19-9 divided by initial serum level of 
bilirubin)[6] were also evaluated. The new defining 
system was applied to check if it could describe the 
tumor extent at the initial diagnosis.
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head cancer involving the pancreatic neck [Exp(B) = 
9.461, P  = 0.001] and arterial invasion [Exp(B) = 6.208, 
P  = 0.010], and adjusted CA19-9 ≥ 50 [Exp(B) = 1.972 
P  = 0.019] were identified as prognostic clinical factors 
to predict tumor recurrence. 
CONCLUSION: The suggested preoperative defining 
system can help with designing treatment plans and 
also predict oncologic outcomes. 
Key words: Preoperative defining system; Pancreas 
head cancer; Borderline resectable; Adjusted CA19-9; 
Neoadjuvant therapy
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Owing to the anatomical complexity of the 
pancreas head cancer, it is not always easy to share the 
exact disease status among multidisciplinary treatment 
members. So, we made a preoperative defining 
system, which contained the important clinical variables 
(resectability, tumor location, vascular relationship, 
adjacent organ involvement, preoperative CA19-9, 
vascular anomaly) to decide the treatment plan for 
pancreas head cancer. Through internal validation, we 
proved that this system could be useful not only to 
clarify the disease characteristics but also to predict 
oncologic outcomes of pancreas head cancer.
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INTRODUCTION
Pancreatic cancer is one of the lethal malignant di-
seases arising from the gastrointestinal tract. It is 
well-known that only margin-negative resection of the 
tumor can lead to long-term survival[1]. However, most 
patients treated with curative pancreatectomy develop 
tumor recurrences, especially in the liver. Therefore, 
effective adjuvant systemic chemotherapy should be 
mandatory[2]. 
In general, resectable pancreatic cancer is defined 
as a clinical tumor condition confined to the pancreas 
without radiologic evidence suggesting invasion 
of the major vascular system or systemic meta-
stases. However, there is some controversy about 
the definition of borderline resectable pancreatic 
cancer[3]. Currently, there are two systems for defining 
borderline resectable pancreatic cancer[4,5]. Whatever 
definition is chosen, surgeons should plan the treat-
ment modality and design the operative approach for 
curative resection based on preoperative radiologic 
assessment. In addition, they need to explain the 
Correlation between new preoperative defining system 
and clinico-oncologic outcomes
Individual clinical components existing in the new 
preoperative defining system, such as radiological 
resectability, tumor size, tumor location, vascular 
involvement, adjacent organ invasion, preoperative 
initial serum CA19-9 level, and initial serum bilirubin 
were correlated with treatment strategy and oncologic 
outcomes.
Statistical analysis
All statistical analyses were performed using IBM® 
SPSS Statistics version 20. Continuous variables were 
indicated as mean ± SD and categorical variables 
as frequency and percentage (%). Student’s t-tests 
and χ 2 tests were used. Logistic regression analysis 
was applied for multivariate analysis. Kaplan-Meier 
and Cox-proportional hazard models were applied for 
disease-free survival as univariate and multivariate 
analysis. P values < 0.05 were considered as stati-
stically significant.
RESULTS
Clinical feasibility of the new preoperative defining 
system
During the study period, 119 patients underwent 
potentially curative resection of pancreatic head 
cancer. All were confirmed as ductal adenocarcinoma 
by pathologic examination. Among them, six patients 
without available preoperative image studies were 
excluded, totally 113 patients were enrolled. The new 
preoperative defining system was applied to describe 
the extent of the tumor and some clinical information 
for all patients. Resectable pancreatic cancer (R) was 
noted in 75 patients (66.4%), borderline resectable 
pancreatic cancer (BR) in 34 (30.1%), and locally 
advanced pancreatic cancer (LA) in four patients 
(3.5%). The mean radiologic tumor size was measured 
as 2.4 ± 0.8 cm in the maximum diameter. Seventy-
three tumors (64.6%) were located in the pancreatic 
head, 35 (31%) in the uncinate process, and five 
(4.4%) in the pancreatic head and neck area. Forty 
patients (35.4%) were found to have tumors involving 
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Figure 1  Clinical application of the new defining system in resected pancreatic head cancer. For example, a patient who has a 2 cm-sized tumor with 
preoperative CA19-9 120 U/mL and initial total bilirubin 1.2 mg/dL can be described according to the proposed new defining system as follows: (A) R2cm-H-120 (1.2); (B) 
BR2cm-Hn-SMV (0.5cm/30%)-120 (1.2); (C) BR2cm-Hu-SMA (0.5 cm/20%)-120(1.2); (D) BR2cm-Hn-SMV (0.5cm/50%)-120 (1.2)-Arha; (E) R2cm-H-pylorus-120 (1.2); 
(F) R2cm-H-T colon mesentery-120 (1.2).
Table 1  Important abbreviations used in the new preoperative 
defining system for pancreatic cancer
Symbol Description Comments
Resectability
   R Resectable
   BR Borderline resectable
   LA Locally advanced
Location
   H Pancreatic head Hu: uncinate process,
Hn: neck portion
Vascular structure
   CA Celiac axis
   CHA Common hepatic artery
   GDA Gastroduodenal artery OGA: origin of 
gastroduodenal artery
   aRHA Aberrant right hepatic 
artery
   Rt/Lt Right/left
   SMA Superior mesenteric 
artery
   SMV Superior mesenteric vein
   SMV-SV-PV Superior mesenteric vein-
splenic vein-portal vein
R: Resectable pancreatic cancer; BR: Resectable pancreatic cancer; LA: 
Locally advanced pancreatic cancer.
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Correlation between clinical components and long-term 
oncologic outcomes
It was also noted that the proposed new defining 
system can be useful in predicting oncologic outcome 
even before confirming pathologic characteristics of 
the resected pancreatic cancer.
Mean disease-free survival was 24.8 mo (95%CI: 
19.6-30.1) with a 5-year disease-free survival rate of 
13.5%. Interestingly, when putting clinical variables 
used in the preoperative defining system into a Cox 
hazard regression model, it was found that anatomic 
resectability, especially borderline resectable pancreatic 
cancer [Exp(B) = 0.222]; radiologic tumor size ≥ 
2.4cm [Exp(B) = 1.696], tumor location, especially 
pancreatic head cancer involving the pancreatic neck 
portion [Exp(B) = 9.461]; radiologic venous vascular 
component [Exp(B) = 2.788]; arterial component 
[Exp(B) = 6.208]; initial total bilirubin ≥ 4.6 [Exp(B) 
= 0.588]; and adjusted CA19-9 ≥ 50 [Exp(B) = 1.972] 
were identified as prognostic clinical factors to predict 
tumor recurrence (Table 4). 
DISCUSSION
TNM staging system is widely accepted, and it is 
aimed at predicting survival. Some kinds of cancer 
cannot be simplified down to a TNM stage because of 
unique anatomical characteristics. One of these is hilar 
cholangiocarcinoma (HCCA) and another is pancreas 
head cancer. For hilar cholangiocarcinoma, there is 
already a presurgical staging system that considers 
surrounding anatomical structures[7]. The Jarnagin-
Blumgart (J-B) classification has been used for 
deciding treatment plans and developing a prognosis 
major vascular structures. Mean initial serum level of 
CA19-9 was found to be 825.7 ± 2037.8 (U/mL), and 
initial serum bilirubin was 4.6 ± 5.0 (mg/dL). Adjusted 
CA19-9 was calculated as 401.9 ± 872.8 (U/mL).
Correlation between clinical components and surgical 
strategy
It was found that the new preoperative defining 
system can help in decision-making about treatment 
strategies and surgical extent in pancreatic cancer 
management.
Thirty-nine patients (34.5%) underwent combined 
venous vascular resection. SMV/PV wedge resection 
was performed in 15 patients, and 24 patients 
underwent segmental resection of the PV system. 
Among the clinical factors used in the new preoperative 
defining system, radiologic tumor size, vascular 
components were associated with combined venous 
vascular resection (P < 0.05, Table 2). However, in 
multivariate analysis, only radiologic tumor size ≥ 2.4 
cm [Exp(B) = 2.288, 95%CI: 1.029-5.087, P = 0.042] 
was noted to be independent clinical factor to predict 
combined venous vascular resection. 
It was also found that resectability, radiologic 
tumor size, tumor location, and radiologic vascular 
component were related to neoadjuvant treatment 
before surgical resection (P < 0.05, Table 3). In 
multivariate analysis, radiologic tumor size ≥ 2.4 cm 
[Exp(B) = 3.608, 95%CI: 1.512-8.609, P = 0.004], 
and radiologic vascular component [Exp(B) = 5.553, 
95%CI: 2.269-14.589, P < 0.001] were found to 
be independent predictive factors for preoperative 
neoadjuvant treatment in this study population. 
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Table 2  Univariate analysis to predict combined venous 
vascular resection in treating pancreatic head cancer
Combined venous vascular 
resection
P  value
No Yes
Resectability
   R 54 21
   BR 17 17
   LA   2   2 0.054
Radiologic tumor size (cm) 2.3 ± 0.7 2.6 ± 0.8 0.044
   Tumor location
   Head 49 24
   Uncinate 22 13
   Including neck   2   3 0.485
Radiologic vascular 
component
   No 52 21
   Yes 21 19 0.002
Initial preoperative serum 
CA19-9
846.7 ± 2193.9 805.3 ± 1761.9 0.919
Initial serum total bilirubin 4.3 ± 5.0 4.9 ± 4.6 0.528
R: Resectable pancreatic cancer; BR: Resectable pancreatic cancer; LA: 
Locally advanced pancreatic cancer.
Table 3  Univariate analysis to predict neoadjuvant treatment 
for pancreatic head cancer
Neoadjuvant treatment P  value
No Yes
Resectability
   R 52 23
   BR 10 24
   LA   1   3 < 0.001
Radiologic tumor size (cm) 2.1 ± 5.7 2.7 ± 0.9 < 0.001
   Tumor location
   Head 46 27
   Uncinate 15 20
   Including neck   2   3    0.049
Radiologic vascular 
component
   No 52 21
   Yes 11 29 < 0.001
Initial preoperative serum 
CA19-9
600.8 ± 1640.6 1109.0 ± 2437.1    0.189
Initial serum total bilirubin 3.9 ± 4.9 5.5 ± 4.9    0.087
R: Resectable pancreatic cancer; BR: Resectable pancreatic cancer; LA: 
Locally advanced pancreatic cancer.
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of HCCA[8]. We need a more appropriate defining 
system for pancreas head cancer rather than the TNM 
stage, something similar to the J-B classification for 
HCCA.
The presented new preoperative defining system 
can suggest the treatment strategy, extent of surgery, 
and even tumor biology in resected pancreatic head 
cancer. It was found that all resected pancreatic head 
cancers could be described according to the new 
preoperative defining system based on a preoperative 
CT scan. In addition, in multivariate analysis, radiologic 
tumor size ≥ 2.4 cm [Exp(B) = 3.608, P = 0.004], 
and radiologic vascular component [Exp(B) = 5.553, 
P < 0.001] were independent predictive factors for 
preoperative neoadjuvant treatment. In particular, 
larger tumor size (tumor size ≥ 2.4 cm) was 
associated with combined venous vascular resection 
[Exp(B) = 2.288, P = 0.042], suggesting that clinical 
components used for the currently proposed new 
defining system can provide important clinical clues 
about treatment strategy and the extent of surgery in 
treating pancreatic cancer.
Most importantly, the current system can predict 
patients’ outcomes without requiring confirmation 
of the clinical stage of the cancer. Considering that 
most prognostic factors are based on pathologic 
characteristics[9-13], such as lymph node metastasis, 
lymph node ratio, perineural invasion, lymphovascular 
invasion, and cell differentiation, the proposing 
preoperative defining system showed that even clinical 
characteristics, such as anatomic resectability (P = 
0.019), tumor location (P = 0.007), and adjusted 
CA19-9 (P = 0.019), which can be estimated 
before surgical intervention, were identified as good 
prognostic markers for predicting tumor recurrence 
(Table 4). 
Adjusted CA19-9 is defined as the value of initial 
CA19-9 level divided by serum total bilirubin. This 
concept was developed because the actual serum level 
of CA19-9 is not reliable in patients with jaundice. 
We already demonstrated that adjusted CA19-9 was 
a prognostic clinical marker in resected pancreatic 
cancer[6], which was shown again in the present 
study. Further clinical investigation based on a large 
population is necessary to define the oncologic 
significance of preoperative adjusted CA19-9.
When applying this new system in cases of 
neoadjuvant treatment, it would be easy and more 
subjective to detect the radiologic responsiveness 
after neoadjuvant treatment in borderline resectable 
pancreatic cancer. If a radiologist described the 
radiologic changes according to the new defining 
system, the surgeon could be well aware of the current 
tumor status compared with the pre-neoadjuvant 
treatment status, which is one of many advantages of 
new system. For example, it can be described in this 
way: BR2cm-Hu-SMV2.5cm/30%-219 (8) → Neo-
BR2cm-Hu-SMV2.0cm/10%-58 (2).
In spite of oncologic significance of lymph node 
metastasis, clinical N-stage (cN-stage) was not 
considered in this system because the accuracy of 
radiologic estimation of lymph node metastasis is 
not high[14,15]. In addition, preoperative cholangitis, 
pancreatitis, and interventional approaches due to 
obstructive cholangio-pancreatopathy can induce 
secondary lymph node enlargement. In fact, lymph 
node metastasis is one of the important prognostic 
factors in resected pancreatic cancer; however, several 
important randomized controlled studies have proven 
that the extent of lymph node dissection could not 
contribute to increasing oncologic outcome[16-18]. 
Therefore, cN-stage will not influence either prognosis 
or the clinical treatment strategy when the tumor is 
regarded as a resectable pancreatic cancer. 
Instead, clinical information on the possibility 
of pylorus involvement or right colonic mesentery 
would be more useful in designing surgical extent. 
Recently, techniques for pyloric-ring resected pancreati-
coduodenectomy[19], subtotal stomach-preserving 
pancreaticoduodenectomy[20], and combined resection 
of ascending colon are clinically available. In addition, 
descriptions of associated vascular anomaly, especially 
an aberrant right hepatic artery, will be another good 
guide for performing safe pancreaticoduodenectomy, 
because this artery is at risk for accidental injury 
during dissection of the hepatoduodenal ligament[21]. 
To design an optimal operation, it is mandatory to 
have exact anatomical delineation preoperatively. 
This proposed preoperative defining system can give 
compact and critical anatomical information to the 
surgical team. 
There are several important flaws in our study. 
First, the new defining system is only based on 
retrospective data of operated patients. Therefore, 
this could not be reflective of all patients seen for 
consideration of surgery. It is needed to validate 
this defining system with all pancreas head cancer 
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Table 4  Oncologic impact of clinical variables used in the 
new preoperative defining system
Clinical variables Exp(B) 95%CI P  value
Resectability 0.019
   BR 0.222 0.073-0.676 0.008
   LA 0.557 0.105-2.955 0.492
Radiologic tumor size (cm) ≥ 2.4 1.696 0.993-2.897 0.053
Tumor location 0.007
   Hu 0.952 0.557-1.629 0.858
   Hn 9.461   2.634-33.976 0.001
Vascular relationship with 0.064
   Venous system 2.788 0.952-8.165 0.061
   Arterial system 6.208   1.562-24.669 0.010
   Both 2.200   0.484-10.006 0.307
CA19-9 ≥ 825 1.709 0.777-3.761 0.183
Total bilirubin ≥ 4.6 0.588 0.339-1.022 0.060
Adjusted CA19-9 ≥ 50 1.972 1.118-3.480 0.019
BR: Resectable pancreatic cancer; LA: Locally advanced pancreatic cancer.
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surgery candidates prospectively. Second, it seems 
to be complicated and difficult to describe. Third, this 
system cannot estimate actual lymph node status. 
However, in the era of the multidisciplinary team 
approach for treating pancreatic cancer, this defining 
system can be useful for improving communication 
among team members, planning the extent of surgery, 
developing the treatment strategy, and defining tumor 
biology. This system needs to be validated on different 
sets of patient data to confirm its clinical feasibility, 
reproducibility, and oncologic meanings.
COMMENTS
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In this multidisciplinary treatment era, it is most important to share the exact 
disease status among multidisciplinary team members for making appropriate 
treatment pathway. When it comes to pancreas head cancer, the anatomical 
complexity surrounding tumor can make it difficult not only to communicate 
with each members of team, but also to decide treatment plan. In this study, 
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pancreas head cancer cases into resectable, borderline resectable or 
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also should be considered preoperatively. 
Innovations and breakthroughs
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recurrence. 
Applications
This study demonstrates the new defining system for pancreas head cancer 
and will help the multidisciplinary board to communicate with each other about 
the individual disease status in a comprehensive way. 
Terminology
Borderline resectable pancreas cancer means there is a possibility of 
incomplete resection because of adjacent vital vessel invasion such as superior 
mesenteric vein, gastroduodenal artery, hepatic artery and superior mesenteric 
artery. 
Peer-review
The authors recommended a good preoperative description system for 
pancreatic cancer patients. This proposal with possible implication in 
neoadjuvant treatment is very remarkable.
REFERENCES
1 Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler 
MW. Curative resection is the single most important factor 
determining outcome in patients with pancreatic adenocarcinoma. 
Br J Surg 2004; 91: 586-594 [PMID: 15122610 DOI: 10.1002/
bjs.44841]
2 Bakkevold KE, Arnesjø B, Dahl O, Kambestad B. Adjuvant 
combination chemotherapy (AMF) following radical resection 
of carcinoma of the pancreas and papilla of Vater--results of a 
controlled, prospective, randomised multicentre study. Eur J 
Cancer 1993; 29A: 698-703 [PMID: 8471327]
3 Lopez NE, Prendergast C, Lowy AM. Borderline resectable 
pancreatic cancer: definitions and management. World J 
Gastroenterol 2014; 20: 10740-10751 [PMID: 25152577 DOI: 
10.3748/wjg.v20.i31.10740]
4 Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane 
CH, Wang H, Lee JE, Pisters PW, Evans DB, Wolff RA. Borderline 
resectable pancreatic cancer: definitions, management, and role of 
preoperative therapy. Ann Surg Oncol 2006; 13: 1035-1046 [PMID: 
16865597 DOI: 10.1245/ASO.2006.08.011]
5 Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, 
Lu DS, Macari M, Megibow AJ, Miller FH, Mortele KJ, Merchant 
NB, Minter RM, Tamm EP, Sahani DV, Simeone DM. Pancreatic 
ductal adenocarcinoma radiology reporting template: consensus 
statement of the society of abdominal radiology and the american 
pancreatic association. Gastroenterology 2014; 146: 291-304.e1 
[PMID: 24355035]
6 Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR. 
The use of adjusted preoperative CA 19-9 to predict the recurrence 
of resectable pancreatic cancer. J Surg Res 2007; 140: 31-35 [PMID: 
17418869 DOI: 10.1016/j.jss.2006.10.007]
7 Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, 
Blumgart LH. Hilar Cholangiocarcinoma: patterns of spread, 
the importance of hepatic resection for curative operation, and a 
presurgical clinical staging system. Ann Surg 1998; 228: 385-394 
[PMID: 9742921]
8 Ding G, Yang Y, Cao L, Chen W, Wu Z, Jiang G. A modified 
Jarnagin-Blumgart classification better predicts survival for 
resectable hilar cholangiocarcinoma. World J Surg Oncol 2015; 13: 
99 [PMID: 25889726 DOI: 10.1186/s12957-015-0526-5]
9 Delcore R, Rodriguez FJ, Forster J, Hermreck AS, Thomas JH. 
Significance of lymph node metastases in patients with pancreatic 
cancer undergoing curative resection. Am J Surg 1996; 172: 
463-48; discussion 463-48; [PMID: 8942545 DOI: 10.1016/
S0002-9610(96)00237-1]
10 Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt 
UT, Makowiec F. The lymph node ratio is the strongest prognostic 
factor after resection of pancreatic cancer. J Gastrointest 
Surg 2009; 13: 1337-1344 [PMID: 19418101 DOI: 10.1007/
s11605-009-0919-2]
11 Nagakawa T, Mori K, Nakano T, Kadoya M, Kobayashi H, 
Akiyama T, Kayahara M, Ohta T, Ueno K, Higashino Y. Perineural 
invasion of carcinoma of the pancreas and biliary tract. Br J Surg 
1993; 80: 619-621 [PMID: 8518906]
12 Garcea G, Dennison AR, Ong SL, Pattenden CJ, Neal CP, Sutton 
CD, Mann CD, Berry DP. Tumour characteristics predictive of 
survival following resection for ductal adenocarcinoma of the 
head of pancreas. Eur J Surg Oncol 2007; 33: 892-897 [PMID: 
17398060 DOI: 10.1016/j.ejso.2007.02.024]
13 Crippa S, Partelli S, Zamboni G, Barugola G, Capelli P, Inama M, 
Bassi C, Pederzoli P, Falconi M. Poorly differentiated resectable 
pancreatic cancer: is upfront resection worthwhile? Surgery 2012; 
152: S112-S119 [PMID: 22766365 DOI: 10.1016/j.surg.2012.05.017]
14 Imai H, Doi R, Kanazawa H, Kamo N, Koizumi M, Masui 
T, Iwanaga Y, Kawaguchi Y, Takada Y, Isoda H, Uemoto S. 
Preoperative assessment of para-aortic lymph node metastasis in 
patients with pancreatic cancer. Int J Clin Oncol 2010; 15: 294-300 
[PMID: 20232101 DOI: 10.1007/s10147-010-0066-5]
15 Kim YC, Park MS, Cha SW, Chung YE, Lim JS, Kim KS, 
Kim MJ, Kim KW. Comparison of CT and MRI for presurgical 
characterization of paraaortic lymph nodes in patients with 
pancreatico-biliary carcinoma. World J Gastroenterol 2008; 14: 
2208-2212 [PMID: 18407595 DOI: 10.3748/wjg.14.2208]
16 Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ, Han 
SS, Yoon DS, Yu HC, Kang KJ, Kim SG, Kim SW. A prospective 
randomized controlled study comparing outcomes of standard 
resection and extended resection, including dissection of the nerve 
plexus and various lymph nodes, in patients with pancreatic head 
6081 July 14, 2016|Volume 22|Issue 26|WJG|www.wjgnet.com
 COMMENTS
Yang SJ et al . Preoperative defining system for pancreas head cancer
cancer. Ann Surg 2014; 259: 656-664 [PMID: 24368638 DOI: 
10.1097/SLA.0000000000000384]
17 Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada 
Y, Miyagawa S, Yamaguchi A, Ishiyama S, Takeda Y, Sakoda 
K, Kinoshita T, Yasui K, Shimada H, Katoh H. Standard versus 
extended lymphadenectomy in radical pancreatoduodenectomy 
for ductal adenocarcinoma of the head of the pancreas: long-term 
results of a Japanese multicenter randomized controlled trial. J 
Hepatobiliary Pancreat Sci 2012; 19: 230-241 [PMID: 22038501 
DOI: 10.1007/s00534-011-0466-6]
18 Michalski CW, Kleeff J, Wente MN, Diener MK, Büchler MW, 
Friess H. Systematic review and meta-analysis of standard and 
extended lymphadenectomy in pancreaticoduodenectomy for 
pancreatic cancer. Br J Surg 2007; 94: 265-273 [PMID: 17318801 
DOI: 10.1002/bjs.5716]
19 Kawai M, Tani M, Hirono S, Okada K, Miyazawa M, Yamaue 
H. Pylorus-resecting pancreaticoduodenectomy offers long-
term outcomes similar to those of pylorus-preserving pancreati-
coduodenectomy: results of a prospective study. World J Surg 
2014; 38: 1476-1483 [PMID: 24370543 DOI: 10.1007/s00268-
013-2420-z]
20 Wu W, Hong X, Fu L, Liu S, You L, Zhou L, Zhao Y. The 
effect of pylorus removal on delayed gastric emptying after 
pancreaticoduodenectomy: a meta-analysis of 2,599 patients. PLoS 
One 2014; 9: e108380 [PMID: 25272034 DOI: 10.1371/journal.
pone.0108380]
21 Shukla PJ, Barreto SG, Kulkarni A, Nagarajan G, Fingerhut A. 
Vascular anomalies encountered during pancreatoduodenectomy: 
do they influence outcomes? Ann Surg Oncol 2010; 17: 186-193 
[PMID: 19838756 DOI: 10.1245/s10434-009-0757-1]
P- Reviewer: Cuadrado-Garcia A, Pantalone D    S- Editor: Yu J 
L- Editor: A    E- Editor: Ma S
6082 July 14, 2016|Volume 22|Issue 26|WJG|www.wjgnet.com
Yang SJ et al . Preoperative defining system for pancreas head cancer
                                      © 2016 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
2  6
